Conference Call Participants
Stephanie Diaz – Vida Strategic Partners, Inc.
Joon Lee
Gregory Renza – Truist Securities, Inc., Research Division
Jack Padovano – Stifel, Nicolaus & Company, Incorporated, Research Division
Nathanael Charoensook – Leerink Partners LLC, Research Division
Hardik Parikh – JPMorgan Chase & Co, Research Division
William Wood – B. Riley Securities, Inc., Research Division
Michael Ulz – Morgan Stanley, Research Division
Timur Ivannikov – Cantor Fitzgerald & Co., Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Xinwei An – Canaccord Genuity Corp., Research Division
Ryan Deschner – Raymond James & Associates, Inc., Research Division
Jiale Song – Jefferies LLC, Research Division
Tsan-Yu Hsieh – William Blair & Company L.L.C., Research Division
Jeet Mukherjee – BTIG, LLC, Research Division
Yale Jen – Laidlaw & Company (UK) Ltd., Research Division
Biren Amin – Piper Sandler & Co., Research Division
Daniel Brims – Lake Street Capital Markets, LLC, Research Division
Presentation
Operator
Welcome to the Viking Therapeutics Third Quarter 2026 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, October 28, 2026. I would now like to turn the conference over to Viking’s Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.
Stephanie Diaz
Vida Strategic Partners, Inc.
Hello, and thank you all for participating in today’s call. Joining me today is Brian Lian, Viking’s President and CEO; Greg Zante, Viking’s CFO; and Hubert Chen, Viking’s Chief Medical Officer.
Before we begin, I’d like to caution that comments made during this conference call today, October 28, 2026, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking’s expectations regarding its development activities, time lines and milestones.
